Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 6/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
| ▸ | CASR | P41180 | 1/20 | 0.30 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL988229 | 1.00 | CYP2D6 (0.38) | CYP2D6SLC6A2SLC6A4NOS2ACACB | |
| SCHEMBL12949374 | 0.79 | KDM1A (0.39) | CYP2D6SLC6A2SLC6A4NOS2PBRM1 | |
| SCHEMBL986079 | 0.78 | ACACB (0.43) | CYP2D6SLC6A2SLC6A4NOS2ACACB | |
| SCHEMBL988223 | 0.76 | CYP2D6 (0.35) | CYP2D6SLC6A2SLC6A4NOS2ACACB | |
| SCHEMBL988222 | 0.76 | CYP2D6 (0.35) | CYP2D6SLC6A2SLC6A4NOS2ACACB | |
| SCHEMBL12923940 | 0.71 | ALDH1A1 (0.35) | CYP2D6SLC6A2SLC6A4NOS2PBRM1 | |
| SCHEMBL987451 | 0.65 | GAA (0.41) | ACACBGAAMEN1KMT2A | |
| SCHEMBL10346414 | 0.63 | CYP1A2 (0.38) | CYP2D6SLC6A2SLC6A4MEN1KMT2A | |
| SCHEMBL10191871 | 0.63 | ACACB (0.46) | ACACBGAA | |
| SCHEMBL12923937 | 0.62 | HTT (0.47) | SLC6A2SLC6A4AOC3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003776-A1 | TETRAHYDROPYRANONAPHTHYRIDINES DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC TREATMENT THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003776-A1 | TETRAHYDROPYRANONAPHTHYRIDINES DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC TREATMENT THEREOF | TPMT, TYMS, QDPR | CYP2D6 83/4885SLC6A2 636/4885SLC6A4 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.